http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2430753-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05b362bb0629d716c16a33d3ac22269c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_100b24d96e1606596c21c07c115d6375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-452 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08 |
| filingDate | 2010-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9650a2cea9d6b54a3affd9c0b91fea8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6119b79528290eaac7a4cd6cdbb69d32 |
| publicationDate | 2011-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2430753-C1 |
| titleOfInvention | Method of anesthetic management in degree iii-iv obesity oncogynaecologic patients |
| abstract | FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anesthesiology, and can be used as an anaesthesia care of surgeries in degree III-IV obesity oncogynaecologic patients with no evident cardiac and pulmonary decompensation. For this purpose, a base type of blood circulation is pre-determined. The patients with hyperkinetic blood circulation require general anaesthesia by introduction of sevoflurane 1.3-1.6 MAK; 2.2-2.5 vol. % fentanyl 1.5-1.8 mcgkghour, myoplegia is performed by introduction of esmerone 0.3-0.33 mgkghour. It is combined with continuous infusion of dalargin during the whole anaesthesia in dose 45-55 mcgkghour. The patients with hypokinetic blood circulation require general anaesthesia that is combined with continuous infusion of dalargin 45-55 mcgkghour during the whole anaesthesia and infusion of magnesium sulphate 0.12-0.15 mmolekg of body weights. ^ EFFECT: method enables adequate, safe and managed anaesthesia in the case patients ensured by haemodynamic stabilisation by determined blood circulation type. ^ 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2681496-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021211006-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2635532-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2649454-C1 |
| priorityDate | 2010-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.